We also found that variable phenotypes were caused by DUOX2 mutations, and there was no relationship between the mutation from DUOX2 and the outcome of patients with CH at reevaluation, which was controversial in previous studies. The gene discussed is DUOX2; the disease is cyclic hematopoiesis.